CervoMed Inc. (NASDAQ:CRVO) saw its shares slide 14.9% in premarket trading Wednesday after announcing a private placement financing totaling $10.5 million and a renewed push to find a strategic partner for its dementia drug program.
Under a securities purchase agreement, the clinical-stage biotech agreed to sell 3,360,377 units at $3.14 per unit. The placement was led by institutional healthcare investors and also included participation from company insiders. Named participants in the financing include Joshua S. Boger, chair of CervoMed’s board of directors, along with trusts related to CEO John J. Alam and board member Sylvie Grégoire.
Each unit will consist of one share of common stock or one pre-funded warrant, and will include Series B and Series C warrants. The Series B warrants carry an exercise price of $3.32 per share and expire on June 11, 2031. The Series C warrants have an exercise price of $3.14 per share with an expiration date of June 11, 2027. The company said if all warrants are exercised for cash, the transactions could yield up to an additional $21.7 million in gross proceeds.
CervoMed specified that net proceeds from the private placement are expected to extend the company’s cash runway into the second quarter of 2027. Management said the funds will also support the company’s strategic priority of securing a partnership to advance neflamapimod into Phase 3 development for dementia with Lewy bodies (DLB).
The company noted prior regulatory alignment relevant to that goal. CervoMed reported alignment with the U.S. Food and Drug Administration on a potential registration pathway for neflamapimod in DLB in November 2025, and similar alignment with U.K. and European regulators in January 2026.
Looking ahead, CervoMed expects over the next six months to receive 24-week biomarker and clinical data from its Phase 2a trial evaluating neflamapimod in nonfluent variant primary progressive aphasia. The company also plans to initiate the EXPERTS-ALS Phase 2a trial in the fourth quarter of 2026.
The private placement is anticipated to close on or about June 11, 2026, subject to customary closing conditions. The company framed the financing and partnership pursuit as steps to support late-stage development of neflamapimod for DLB.
About the financing and near-term milestones
- The transaction consists of 3,360,377 units priced at $3.14 each.
- Insider participation includes the board chair and trusts tied to the CEO and a board member.
- Warrants included in the units could bring up to $21.7 million in additional gross proceeds if exercised.
- Key near-term data expected: 24-week biomarker and clinical readouts from a Phase 2a trial within six months; EXPERTS-ALS Phase 2a initiation planned for Q4 2026.